193 related articles for article (PubMed ID: 32948502)
1. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
Bursać S; Prodan Y; Pullen N; Bartek J; Volarević S
Trends Cancer; 2021 Jan; 7(1):57-76. PubMed ID: 32948502
[TBL] [Abstract][Full Text] [Related]
2. p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways.
Lindström MS; Bartek J; Maya-Mendoza A
Cell Death Differ; 2022 May; 29(5):972-982. PubMed ID: 35444234
[TBL] [Abstract][Full Text] [Related]
3. Perturbation of RNA Polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells.
Turi Z; Senkyrikova M; Mistrik M; Bartek J; Moudry P
Cell Cycle; 2018; 17(1):92-101. PubMed ID: 29143558
[TBL] [Abstract][Full Text] [Related]
4. Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
Kusnadi EP; Trigos AS; Cullinane C; Goode DL; Larsson O; Devlin JR; Chan KT; De Souza DP; McConville MJ; McArthur GA; Thomas G; Sanij E; Poortinga G; Hannan RD; Hannan KM; Kang J; Pearson RB
EMBO J; 2020 Nov; 39(21):e105111. PubMed ID: 32945574
[TBL] [Abstract][Full Text] [Related]
5. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.
Woods SJ; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2015 Jul; 1849(7):821-9. PubMed ID: 25464032
[TBL] [Abstract][Full Text] [Related]
6. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
Domostegui A; Peddigari S; Mercer CA; Iannizzotto F; Rodriguez ML; Garcia-Cajide M; Amador V; Diepstraten ST; Kelly GL; Salazar R; Kozma SC; Kusnadi EP; Kang J; Gentilella A; Pearson RB; Thomas G; Pelletier J
Blood; 2021 Jun; 137(24):3351-3364. PubMed ID: 33512431
[TBL] [Abstract][Full Text] [Related]
7. The Effects of Deregulated Ribosomal Biogenesis in Cancer.
Lu Y; Wang S; Jiao Y
Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002277
[TBL] [Abstract][Full Text] [Related]
8. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis.
Bursac S; Brdovcak MC; Donati G; Volarevic S
Biochim Biophys Acta; 2014 Jun; 1842(6):817-30. PubMed ID: 24514102
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content.
Morcelle C; Menoyo S; Morón-Duran FD; Tauler A; Kozma SC; Thomas G; Gentilella A
Cancer Res; 2019 Sep; 79(17):4348-4359. PubMed ID: 31292158
[TBL] [Abstract][Full Text] [Related]
10. Targeting the nucleolus for cancer intervention.
Quin JE; Devlin JR; Cameron D; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2014 Jun; 1842(6):802-16. PubMed ID: 24389329
[TBL] [Abstract][Full Text] [Related]
11. Growth control and ribosomopathies.
Teng T; Thomas G; Mercer CA
Curr Opin Genet Dev; 2013 Feb; 23(1):63-71. PubMed ID: 23490481
[TBL] [Abstract][Full Text] [Related]
12. Acrolein preferentially damages nucleolus eliciting ribosomal stress and apoptosis in human cancer cells.
Wang HT; Chen TY; Weng CW; Yang CH; Tang MS
Oncotarget; 2016 Dec; 7(49):80450-80464. PubMed ID: 27741518
[TBL] [Abstract][Full Text] [Related]
13. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
14. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
15. p53 induces a survival transcriptional response after nucleolar stress.
Liao H; Gaur A; Mauvais C; Denicourt C
Mol Biol Cell; 2021 Oct; 32(20):ar3. PubMed ID: 34319761
[TBL] [Abstract][Full Text] [Related]
16. Ribosome biogenesis and cancer: basic and translational challenges.
Bustelo XR; Dosil M
Curr Opin Genet Dev; 2018 Feb; 48():22-29. PubMed ID: 29100209
[TBL] [Abstract][Full Text] [Related]
17. Ribosome biogenesis in cancer: new players and therapeutic avenues.
Pelletier J; Thomas G; Volarević S
Nat Rev Cancer; 2018 Jan; 18(1):51-63. PubMed ID: 29192214
[TBL] [Abstract][Full Text] [Related]
18. PIM1 destabilization activates a p53-dependent response to ribosomal stress in cancer cells.
Sagar V; Caldarola S; Aria V; Monteleone V; Fuoco C; Gargioli C; Cannata S; Loreni F
Oncotarget; 2016 Apr; 7(17):23837-49. PubMed ID: 26993775
[TBL] [Abstract][Full Text] [Related]
19. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
20. Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders.
Calo E; Gu B; Bowen ME; Aryan F; Zalc A; Liang J; Flynn RA; Swigut T; Chang HY; Attardi LD; Wysocka J
Nature; 2018 Feb; 554(7690):112-117. PubMed ID: 29364875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
